Consensus Grifols, S.A.

Equities

GRF

ES0171996087

Market Closed - BME Other stock markets 09:07:23 12/09/2024 pm IST			After market 10:36:27 pm
10.02 ^EUR	+2.16%		9.960	-0.60%

05:28pm	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT
11/09	European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading	MT

Evolution of the Average Target: Grifols, S.A.

Evolution of the Target Price: Grifols, S.A.

Changes in Analyst Recommendations: Grifols, S.A.

b3a8852a9a4fb5a1cad94194995bb._AVzE1zo3ZmsqJ0PfplpZ-7mf7FmmOf5L6SxLcAlg2c.yksxVAaA8KrWy8hWEN0lC6WBEIgBqNLAfOffd_Bdxgq9RjV4D56Lq-nYxA~c4be3df2074b1e2595a282fe701b3eb4

Analysts' recommendations: Grifols, S.A.

GRIFOLS : Operational improvements continued in the Q2; guidance maintained	31/07
GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion?	08/07
Trending : Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker	08/07	DJ
Grifols Stakeholder Scranton Enterprises Said in Talks for EUR130 Million Loan	03/07	MT
GRIFOLS : In line Q1 and on track deleveraging; worth a go	15/05
Grifols shares fall after new Gotham City Research report	14/05	RE
GRIFOLS : Factoring in a more moderate earnings recovery; long-term view intact	11/04
Invest Securities Keeps Grifols at Buy, Trims PT	01/03	MT
GRIFOLS : Market panic following yesterday’s conference call was unwarranted	01/03
GRIFOLS : adjusted target price at Invest Securities	01/03	CF
GRIFOLS : Q4 in line; today’s adverse market reaction means a buying opportunity	29/02
GRIFOLS : Grifols accelerates its governance improvements post the short-seller’s allegations	07/02
GRIFOLS : Investors not impressed with the conference call; panic opens up attractive entry point	12/01
GRIFOLS : Dragged down by a short seller, but the management is ready to respond	10/01
GRIFOLS : Delivering on a much-needed deleveraging promise	02/01
GRIFOLS : Delivering on a much-needed deleveraging promise	02/01
JPMorgan Adjusts Grifols' Price Target to $10.50 From $10, Maintains Neutral Rating	05/12	MT
GRIFOLS : Persistently-high interest rate impacts our near-term estimates; fundamentals remain intact	07/11
Invest Securities Trims Grifols PT, Maintains Buy Rating	03/11	MT
GRIFOLS : Healthy Q3; deleveraging priorities remain on track	03/11
GRIFOLS : Good Q2; now all eyes on potential divestments	27/23/27
GRIFOLS : Spanish plasma giant making (gradual) progress	14/23/14
GRIFOLS : A potential divestment – a sigh of relief for investors	14/23/14
GRIFOLS : Upbeat Q1 a much-needed boost to investor confidence	09/23/09
GRIFOLS : Recovery on track, despite some recent concerns	03/23/03

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	GRIFOLS, S.A.					+80.67%
	CSL LIMITED					+5.46%
	SAMSUNG BIOLOGICS CO.,LTD.					+8.26%
	UCB					+1.77%
	BIOGEN INC.					+36.33%
	BIOMARIN PHARMACEUTICAL INC.					+31.65%
	BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.					-8.97%
	INCYTE CORPORATION					+17.49%
	ALTEOGEN INC.					-11.22%
	SWEDISH ORPHAN BIOVITRUM AB					+3.24%
	Average					+16.47%
	Weighted average by Cap.					+11.15%